Unichem LaboratoriesNSE:UNICHEMLAB -0.13%65 Days Payable is 121.42 as of Mar. 2026, which is 22% below its 10-year median of 154.78. GuruFocus rates NSE:UNICHEMLAB with a GF Score™ of 65/100 and a GF Value™ of ₹688.18 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Unichem Laboratories ranks better than 68.7% on this metric.
The historical rank and industry rank for Unichem Laboratories's Days Payable or its related term are showing as below:
NSE:UNICHEMLAB'
s Days Payable Range Over the Past 10 Years
Min: 128.47 Med: 154.78 Max: 220.25
Current: 128.47
During the past 13 years, Unichem Laboratories's highest Days Payable was 220.25. The lowest was 128.47. And the median was 154.78.
NSE:UNICHEMLAB's Days Payable is ranked better than 68.7% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:UNICHEMLAB: 128.47
Unichem Laboratories's Days Payable
declined
from Mar. 2025 (138.84) to Mar. 2026 (121.42).
It may suggest that Unichem Laboratoriesaccelerated paying its suppliers.
Unichem Laboratories Days Payable Related Terms
Unichem Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Unichem Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:UNICHEMLAB vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unichem Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unichem Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unichem Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Unichem Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Unichem Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unichem Laboratories (NSE:UNICHEMLAB) has a Days Payable of 121.42 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Unichem Laboratories and its competitors. This is 22% below median its historical median of 154.78. Over the past decade, Unichem Laboratories' Days Payable has ranged from 128.47 to 220.25. According to the industry distribution chart, Unichem Laboratories ranks #288 out of 920 companies in the Drug Manufacturers industry, placing it in the top 31.3%.
Is Unichem Laboratories' Days Payable too high?
Unichem Laboratories' current Days Payable of 121.42 is 22% below median its 10-year median of 154.78. Over the past 10 years, this metric has ranged from a low of 128.47 to a high of 220.25. The Drug Manufacturers industry median Days Payable is 90.84. Unichem Laboratories' value of 121.42 is 33.7% above this industry median. Based on the distribution chart, Unichem Laboratories ranks #288 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Unichem Laboratories has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Unichem Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unichem Laboratories ranks #288 out of 920 companies for Days Payable. This puts Unichem Laboratories in the upper half of its industry. The industry median Days Payable is 90.84. Unichem Laboratories' value of 121.42 is 33.7% above this benchmark. Historically, Unichem Laboratories' own Days Payable has ranged from 128.47 to 220.25 over the past decade. While the company's 10-year median is 154.78 vs. the industry median of 90.84, Unichem Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unichem Laboratories's current Days Payable of 121.42 is 33.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Unichem Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unichem Laboratories's current Days Payable is 121.42, which is 22% below median its own 10-year median of 154.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unichem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Unichem Laboratories (NSE:UNICHEMLAB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹688.18, compared to a current price of ₹433.00 — trading 37.1% below its estimated fair value. The current Days Payable is 121.42, which is 22% below median its 10-year median of 154.78 and 33.7% above the Drug Manufacturers industry median of 90.84. Unichem Laboratories' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Unichem Laboratories (NSE:UNICHEMLAB), the current Days Payable is 121.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unichem Laboratories (NSE:UNICHEMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Unichem Laboratories stock appears to be undervalued.
The current stock price of ₹433.00 is trading 37.1% below its estimated GF Value™ of ₹688.18.
GuruFocus considers Unichem Laboratories to be Significantly Undervalued.
Key valuation signals for NSE:UNICHEMLAB:
Days Payable: 121.42 (22% below median its 10-year median of 154.78)
GF Value™: ₹688.18 vs. price of ₹433.00 (37.1% below fair value)
Industry Position: 33.7% above the Drug Manufacturers median (#288 of 920)
No single metric tells the full story. See the NSE:UNICHEMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.
65GF Score
Get the complete analysis for NSE:UNICHEMLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:UNICHEMLAB has been successfully added to your 
